Following the publication of its first preclinical results in metachromatic leukodystrophy, a rare genetic disorder typically affecting young children, Release Therapeutics has raised CHF 3.3 million in seed funding from private investors. The funds will into further studies and advancements as the company drives towards its mission of treating genetic disorders without gene therapies.
